Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Rebif, avonex, rebif rebidose
Synonyms :
Interferon beta-1a
Class :
interferons
Dosage Forms & StrengthsÂ
Prefilled intramuscular syringeÂ
30mcg/0.5mlÂ
Prefilled intramuscular autoinjector penÂ
30mcg/5mlÂ
Prefilled subcutaneous syringe titration packÂ
8.8mcg/0.2mlÂ
22mcg/0.5mlÂ
Powder for injectionÂ
30mcg/vialÂ
Prefilled subcutaneous syringeÂ
22mcg/0.5mlÂ
44mcg/0.5mlÂ
Prefilled subcutaneous autoinjectorÂ
8.8mcg/syringeÂ
22mcg/syringeÂ
44mcg/syringeÂ
Rebif 22mcg
Weeks 1-2: 4.4 mcg subcutaneous thrice a week
Weeks 3-4: 11 mcg subcutaneous thrice a week
Over Week 5: 22 mcg subcutaneous thrice a week
Rebif 44mcg
Weeks 1-2: 8.8 mcg subcutaneous thrice a week
Weeks 3-4: 22 mcg subcutaneous thrice a week
Over Week 5: 44 mcg subcutaneous thrice a week
Avonex
30mcg intramuscular every week
Dosage Forms & StrengthsÂ
Prefilled intramuscular syringeÂ
30mcg/0.5mlÂ
Prefilled intramuscular autoinjector penÂ
30mcg/5mlÂ
Prefilled subcutaneous syringe titration packÂ
8.8mcg/0.2mlÂ
22mcg/0.5mlÂ
Powder for injectionÂ
30mcg/vialÂ
Prefilled subcutaneous syringeÂ
22mcg/0.5mlÂ
44mcg/0.5mlÂ
Prefilled subcutaneous autoinjectorÂ
8.8mcg/syringeÂ
22mcg/syringeÂ
44mcg/syringeÂ
Avonex
30mcg intramuscular every week
Rebif 22mcg
Weeks 1-2: 4.4 mcg subcutaneous thrice a week
Weeks 3-4: 11 mcg subcutaneous thrice a week
Over Week 5: 22 mcg subcutaneous thrice a week
Rebif 44mcg
Weeks 1-2: 8.8 mcg subcutaneous thrice a week
Weeks 3-4: 22 mcg subcutaneous thrice a week
Over Week 5: 44 mcg subcutaneous thrice a week
may increase the toxic effect
may increase the toxic effect
may increase the toxic effect
Frequency defined:Â Â
>10%Â
HeadacheÂ
Muscle acheÂ
Urinary tract infectionÂ
FeverÂ
DiarrheaÂ
InfectionÂ
Injection site reactionÂ
Flu-like syndromeÂ
NauseaÂ
Pain Â
AstheniaÂ
DizzinessÂ
DyspepsiaÂ
1-10%Â
AnemiaÂ
Chest painÂ
Abdominal painÂ
<1%Â
Aggravation of seizure disordersÂ
Post-marketing reportsÂ
Hemolytic anemiaÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: Interferon beta-1aÂ
Pronounced: [ in-ter-FEAR-on-BAY-ta ]Â
Why do we use Interferon beta-1a?Â
Interferon beta-1a is a medication used to treat relapsing forms of multiple sclerosis (MS). It is a protein called a cytokine produced naturally by the body to help fight viral infections and other diseases. Interferon beta-1a modifies the immune system’s response to the body’s tissues, which can help reduce inflammation and damage to the central nervous system. It is usually given as an injection under the skin or into a muscle and is typically used with other MS medications.Â